Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis

Circulation Research

Volumn 95, Issue 1, 2004, Pages 109-116

  Distler, Oliver ^a   Distler, Jörg H W ^a   Scheid, Annette ^b   Acker, Till ^c,d   Hirth, Astrid ^a   Rethage, Janine ^a   Michel, Beat A ^a   Gay, Renate E ^a   Müller Ladner, Ulf ^e   Matucci Cerinic, Marco ^f   Plate, Karl H ^d   Gassmann, Max ^b   Gay, Steffen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; Hypoxia inducible transcription factor 1; Vascular endothelial growth factor

Indexed keywords

CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1BETA; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; OXYGEN TENSION; POLAROGRAPHY; PRIORITY JOURNAL; SKIN CAPILLARY; SYSTEMIC SCLEROSIS;

CELL HYPOXIA; CYTOKINES; DERMIS; DNA-BINDING PROTEINS; FIBROBLASTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PHYSIOLOGIC; NUCLEAR PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SKIN; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3142670517     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000134644.89917.96     Document Type: Article

References (35)

1. Furst DE, Clements PJ. Pathogenesis, Fusion (Summary). In: Furst DE, Clements PJ, eds. Systemic Sclerosis. Baltimore, Md: Williams & Wilkins; 1996:275-284.
2. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum. 2003:48:3023-3030.
3. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol. 2003;21: S32-S38.
4. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am. 1996;22:675-694.
5. Distler J, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47:149-161.
6. Hofer T, Wenger H, Gassmann M. Oxygen sensing, HIF-1alpha stabilization and potential therapeutic strategies. Pflugers Arch. 2002;443:503-507.
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the Am Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-590.
8. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
9. Kowal-Bielecka O, Distler O, Neidhart M, Kunzler P, Rethage J, Nawrath M, Carossino A, Pap T, Muller-Ladner U, Michel BA, Sierakowski S, Matucci-Cerinic M, Gay RE, Gay S. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum. 2001;44:1865-1875.
10. Camenisch G, Tini M, Chilov D, Kvietikova I, Srinivas V, Caro J, Spielmann P, Wenger RH, Gassmann M. General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia-inducible factor 1alpha. FASEB J. 1999;13:81-88.
11. Distler JH, Hagen C, Hirth A, Muller-Ladner U, Lorenz HM, Del Rosso A, Michel BA, Gay RE, Nanagara R, Nishioka K, Matucci-Cerinic M, Kalden JR, Gay S, Distler O. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-κB and simian virus 40 promoter factor 1 pathways. Mol Pharmacol. 2004;65:389-399.
12. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19:5435-5443.
13. Brown LF, Harrist TJ, Yeo KT, Stahle-Backdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol. 1995;104:744-749.
14. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16:1151-1162.
15. Aotsuka S, Nakamura K, Nakano T, Kawakami M, Goto M, Okawa-Takatsuji M, Kinoshita M, Yokohari R. Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases. Ann Rheum Dis. 1991;50:27-31.
16. Gay S, Jones RE, Jr., Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol. 1989;92:301-303.
17. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, LeRoy EC, Sutherland S, Silver RM. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995;22:1876-1883.
18. Umehara H, Kumagai S, Murakami M, Suginoshita T, Tanaka K, Hashida S, Ishikawa E, Imura H. Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthritis Rheum. 1990;33:893-897.
19. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999:13:9-22.
20. Mackiewicz Z, Sukura A, Povilenaite D, Ceponis A, Virtanen I, Hukkanen M, Konttinen YT. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002;20:641-646.
21. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Bruhlmann P, Muller-Ladner U, Gay S, Matucci-Cerinic M. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4:R11.
22. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol. 2002;116:796-802.
23. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003:63:3121-3126.
24. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000;43:889-893.
25. Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, Goldblum SE. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol. 2002;29:2565-2570.
26. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat Med. 2000:6:1102-1103.
27. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002;21:1939-1947.
28. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci U S A. 1995;92:7657-7661.
29. Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, Manseau EJ, Dvorak AM, Dvorak HF. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol. 2001;158:1145-1160.
30. Kissin EY, Korn JH. Fibrosis in scleroderma. Rheum Dis Clin North Am. 2003;29:351-369.
31. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994;269:6271-6274.
32. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15:1312-1314.
33. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445-2453.
34. Hofer T, Wenger RH, Kramer MF, Ferreira GC, Gassmann M. Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. Blood. 2003;101:348-350.
35. Distler J, Hirth A, Scheid A, Del Rosso A, Gay RE, Lorenz HM, Kalden JR, Matucci-Cerinic M, Gassmann M, Gay S, Distler O. Expression profile of SSc fibroblasts reveals extracellular matrix proteins as down-stream molecules of hypoxia induced pathways. Arthritis Rheum. 2002;46:S203. Abstract.